We Think Nanjing Hicin Pharmaceutical's (SZSE:300584) Profit Is Only A Baseline For What They Can Achieve

When companies post strong earnings, the stock generally performs well, just like Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) stock has recently. We have done some analysis, and we found several positive factors beyond the profit numbers.

View our latest analysis for Nanjing Hicin Pharmaceutical

The Impact Of Unusual Items On Profit

For anyone who wants to understand Nanjing Hicin Pharmaceutical's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by CN¥6.7m due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If Nanjing Hicin Pharmaceutical doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Nanjing Hicin Pharmaceutical.

Our Take On Nanjing Hicin Pharmaceutical's Profit Performance

Unusual items (expenses) detracted from Nanjing Hicin Pharmaceutical's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Nanjing Hicin Pharmaceutical's statutory profit actually understates its earnings potential! And the EPS is up 17% over the last twelve months. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Nanjing Hicin Pharmaceutical at this point in time. Case in point: We've spotted 1 warning sign for Nanjing Hicin Pharmaceutical you should be aware of.

Today we've zoomed in on a single data point to better understand the nature of Nanjing Hicin Pharmaceutical's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.